ACR criteria | Diagnosis (months) | APF + (months) | Difference (months) | APF titre | Latex (IU) | Rose-Waaler (IU) |
5 | 1 | - | - | - | - | |
4 | 4 | - | - | - | - | |
4 | 5 | - | - | - | - | |
4 | 26 | - | - | - | - | |
4 | 35 | - | - | - | - | |
4 | 39 | - | - | - | - | |
4 | 40 | - | - | - | - | |
4 | 41 | - | - | - | - | |
5 | 2 | - | - | 100 | 64 | |
4 | 24 | 26 | 2 | 1:5000 | 100 | 32 |
5 | 11 | 12 | 1 | 1:500 | 50 | 64 |
4 | 2 | 2 | 0 | 1:1000 | 50 | 0 |
6 | 2 | 2 | 0 | 1:100 | 100 | 32 |
6 | 3 | 3 | 0 | 1:10 000 | 100 | 16 |
4 | 3 | 3 | 0 | 1:100 | 0 | 0 |
4 | 5 | 5 | 0 | 1:200 | 25 | 32 |
4 | 5 | 5 | 0 | 1:100 | 0 | 0 |
4 | 5 | 5 | 0 | 1:2000 | 100 | 0 |
5 | 6 | 6 | 0 | 1:100 | 0 | 0 |
4 | 7 | 7 | 0 | 1:1000 | 0 | 32 |
4 | 10 | 10 | 0 | 1:200 | 0 | 0 |
6 | 11 | 11 | 0 | 1:500 | 50 | 64 |
5 | 1 | 0 | −1 | 1:2000 | 50 | 0 |
4 | 8 | 6 | −2 | 1:500 | 50 | 64 |
4 | 8 | 5 | −3 | 1:200 | 50 | 0 |
4 | 8 | 6 | −2 | 1:100 | 0 | 0 |
4 | 9 | 8 | −1 | 1:500 | 0 | 0 |
4 | 10 | 6 | −4 | 1:1000 | 100 | 32 |
5 | 11 | 0 | −11 | 1:500 | 0 | 0 |
4 | 12 | 6 | −6 | 1:10 000 | 100 | 64 |
4 | 13 | 6 | −7 | 1:500 | 50 | 0 |
4 | 14 | 5 | −9 | 1:100 | 0 | 0 |
4 | 15 | 9 | −6 | 1:100 | 50 | 32 |
4 | 16 | 12 | −4 | 1:100 | 0 | 0 |
4 | 17 | 9 | −8 | 1:1000 | 0 | 0 |
4 | 17 | 2 | −15 | 1:500 | 0 | 0 |
4 | 26 | 10 | −16 | 1:500 | 100 | 64 |
4 | 29 | 20 | −9 | 1:200 | 50 | 32 |
4 | 40 | 25 | −15 | 1:2000 | 100 | 128 |
4 | 41 | 1 | −40 | 1:100 | 50 | 32 |
ACR, American College of Rheumatology; APF, antiperinuclear factors.